Clinical Trial

NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

Study acronym: NISTIPS
Recruiting
View on ClinicalTrials.gov →
Summary
The NISTIPS TRITICC-4 study is a prospective, multicentre, non-interventional cohort study to analyze the effectiveness of transjugular intrahepatic portosystemic shunting (TIPS) in patients with Hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab as first-line treatment. It will further characterize the effectiveness of atezolizumab and bevacizumab therapy, investigate post-market safety and evaluate health-related quality in HCC patient cohorts with or without TIPS in a real-world setting.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-16.
Status change: Not Yet Recruiting → Recruiting 2026-02-03
Trial Details
NCT Number NCT07365930
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: Roche Pharma AG, Heinrich-Heine University, Duesseldorf
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 350 participants
Start Date 2025-12-17
Primary Completion 2031-12-17 (estimated)
Study Completion 2031-12-17 (estimated)
Updated on ClinicalTrials.gov 2026-02-05